GlaxoSmithKline

What they do

GlaxoSmithKline (GSK) engages in corporate venture capital activities through multiple channels. Historically, its primary venture arm was SR One, which was founded in 1985 and invested globally in emerging life science companies. In 2020, SR One completed a spin-out from GSK to become an independent firm, though GSK remains a significant limited partner, investing in its funds. Additionally, in 2013, GSK launched Action Potential Venture Capital (APVC), a $50 million strategic fund dedicated to investing in companies developing bioelectronic medicines and technologies. GSK also directly acquires and collaborates with biotech companies, with notable acquisitions including Tesaro, an oncology-focused company, and Bellus Health. The companys investment and partnering focus aligns with its core R&D areas, including oncology, immunology, respiratory diseases, and vaccines.

What they look for

GSK aims to "unite science, technology, and talent to get ahead of disease together." Their capital deployment is strictly strategic, targeting assets that bolster their core therapeutic areas. They do not invest for purely financial returns; every deal must have a clear path to integration with their R&D pipeline.

Stage

Seed, Series B+

Sectors

Healthcare, AI

Based

Brentford, GB